Recently, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen") announced that it has completed the se
2021-12-30Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen) recently announced that the world's first anti-CD3
2021-11-22Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen) announced today that its self-developed Chinese cl
2021-11-19Beijing R&D Center, Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. Officially established.
Sumgen Biotech completed Angel round investment.
Sumgen Biotech was selected in“5050 Plan” of Hangzhou High-tech Zone (Binjiang).
Sumgen completed Series A financing , Led by Shanghai CCB Equity Investment Management Co., Ltd. as exclusive investor.
SG001 obtained NMPA IND approval.
Sumgen established partnership for SG001 with CSPC；
Hangzhou CMC R&D center was officially established.
Sumgen was designated as 1 of the science and technology SMEs in Zhejiang Province.
Sumgen completed Series A+ Financing, Led by China National Biotech Group (CNBG) as strategic investor.
First patient dosed in SG001 clinical trial jointly developed by Sumge and CSPC.
Sumgen was accredited by the National Intellectual Property Management System.
Sumgen was certified by Hangzhou Enterprise High-tech R&D Center.
Sumgen was recognized as one of China's Top 50 Medical and Healthcare Innovation Enterprises.
Sumgen was designated as Hangzhou High-Tech Enterpris.
Sumgen was listed among the 2020 Key R&D Projects of Zhejiang and obtained a support grant;
Sumgen was recognized as National High-Tech Enterprise;
Sumgen Monoclonal Antibody was recognized as National High-tech Enterprises;
Sumgen was designated as Hangzhou Patent Demonstration Enterprise.
Hangzhou Sumgen Biotech Co., Ltd. and CNBG set up the joint venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. ("CNBG Sumgen") .
The construction of an antibody industrialization base was launched.
Series B Financing (RMB 220 million) was completed to accelerate product development and industrialization of innovative products.
SG301 was approved in US for clinical trial.
SG404 was approved for clinical trials in China;
Sumgen was recognized as one of the Top 50 Innovative Biomedicine Enterprises of 2020 in China;
Sumgen was selected as director unit of the Biomedical Innovation Alliance (BIA) of Hangzhou High-tech Zone (Binjiang).
Clinical trial of SG404 was initiated at Beijing Cancer Hospital.
SG404 was approved by the US FDA for clinical trial.
SG12473 obtained IND in both China and the United States;
Sumgen was named of Hangzhou Unicorn Enterprise.
First patient was enrolled in the clinical trial of innovative drug SG12473;
SG301 was approved by the CN IND for clinical trial.
First patient was enrolled in the clinical trial of innovative drug SG301;
SG2501 was approved by the US FDA for clinical trial.
Series B + Funding of 200 million secured to accelerate clinical development and industrialization of pipeline assets;
Sumgen was selected as one of the top 100 pharmaceutical innovation seed enterprises in China in 2021.
Sumgen was certified by Zhejiang Enterprise Research Institute in Jan. 2021;
Sumgen was certified by Hangzhou Enterprise Technology Center in 2021.
Core Capabilities from Antibody Discovery to Clinical Development.
Discover MoreCopyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044